Mariner Wealth Advisors Stake in Keycorp New (KEY) Has Lowered by $3.03 Million; As Chemocentryx (CCXI) Share Price Rose, Shareholder Baker Bros Advisors LP Decreased Its Position

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Baker Bros Advisors Lp decreased its stake in Chemocentryx Inc. (CCXI) by 50% based on its latest 2018Q4 regulatory filing with the SEC. Baker Bros Advisors Lp sold 207,000 shares as the company’s stock rose 6.99% with the market. The hedge fund held 207,029 shares of the health care company at the end of 2018Q4, valued at $2.26M, down from 414,029 at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Chemocentryx Inc. for a number of months, seems to be less bullish one the $748.13M market cap company. The stock decreased 1.29% or $0.17 during the last trading session, reaching $12.96. About 105,621 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since April 15, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Mariner Wealth Advisors Llc decreased its stake in Keycorp New (KEY) by 75.37% based on its latest 2018Q4 regulatory filing with the SEC. Mariner Wealth Advisors Llc sold 216,744 shares as the company’s stock declined 6.05% while stock markets rallied. The institutional investor held 70,827 shares of the major banks company at the end of 2018Q4, valued at $1.05 million, down from 287,571 at the end of the previous reported quarter. Mariner Wealth Advisors Llc who had been investing in Keycorp New for a number of months, seems to be less bullish one the $16.70 billion market cap company. The stock decreased 1.22% or $0.21 during the last trading session, reaching $16.67. About 4.14 million shares traded. KeyCorp (NYSE:KEY) has declined 17.86% since April 15, 2018 and is downtrending. It has underperformed by 22.23% the S&P500. Some Historical KEY News: 23/04/2018 – KEYCORP KEY.N : MORGAN STANLEY RAISES TARGET PRICE TO $25 FROM $24.5; 30/05/2018 – Ryder Presenting at KeyCorp Conference Tomorrow; 24/05/2018 – Forward Air Presenting at KeyCorp Conference May 31; 19/04/2018 – KEYCORP – QTRLY TAXABLE EQUIVALENT NET INTEREST INCOME $952 MLN VS $929 MLN REPORTED LAST YEAR; 14/05/2018 – Watts Water Presenting at KeyCorp Conference May 30; 30/05/2018 – Ferro Presenting at KeyCorp Conference Tomorrow; 21/03/2018 – KeyCorp Raises Its Prime Lending Rate to 4.75 %; 19/04/2018 – KeyCorp Reports First Quarter 2018 Net Income Of $402 Million, Or $.38 Per Common Share; 25/05/2018 – Harsco Presenting at KeyCorp Conference May 30; 23/05/2018 – Beacon Roofing Presenting at KeyCorp Conference May 29

Since October 16, 2018, it had 0 buys, and 7 insider sales for $1.80 million activity. KANAYA SUSAN M also sold $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares. On Tuesday, October 16 GLAXOSMITHKLINE PLC sold $85.85M worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 7.34M shares. Another trade for 36,762 shares valued at $447,092 was sold by Schall Thomas J..

Baker Bros Advisors Lp, which manages about $8.20 billion and $12.21B US Long portfolio, upped its stake in Zymeworks Inc. by 397,387 shares to 1.71M shares, valued at $25.08 million in 2018Q4, according to the filing. It also increased its holding in Ra Pharmaceuticals Inc. by 645,161 shares in the quarter, for a total of 823,113 shares, and has risen its stake in Biomarin Pharmaceutical Inc. (NASDAQ:BMRN).

Investors sentiment decreased to 0.93 in Q4 2018. Its down 0.05, from 0.98 in 2018Q3. It fall, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Federated Pa invested in 65,761 shares or 0% of the stock. Swiss Bancshares has 38,400 shares for 0% of their portfolio. Sio Capital Lc holds 0.67% or 169,257 shares. Renaissance Techs Ltd Liability has 883,381 shares. State Street Corp accumulated 487,355 shares or 0% of the stock. Invesco owns 143,834 shares for 0% of their portfolio. Arrowstreet Cap Lp has invested 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Bvf Il, California-based fund reported 6.69 million shares. Ameriprise accumulated 264,496 shares. Pdts Prtnrs Limited Liability Corp reported 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Alps Advsr holds 0.01% or 156,559 shares in its portfolio. 1,170 are held by Dorsey Wright &. Credit Suisse Ag reported 10,418 shares. Millennium Mgmt Limited Com invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Macquarie Gru stated it has 3,800 shares.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Benzinga.com which released: “52 Biggest Movers From Yesterday – Benzinga” on March 26, 2019, also Benzinga.com with their article: “Cancer Biology Clinical Research Seeking Answers at Cellular Level – Benzinga” published on March 26, 2019, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For March 27, 2019 – Benzinga” on March 27, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” published on March 28, 2019 as well as Benzinga.com‘s news article titled: “10 Biggest Price Target Changes For Wednesday – Benzinga” with publication date: March 27, 2019.

Investors sentiment decreased to 0.81 in Q4 2018. Its down 0.23, from 1.04 in 2018Q3. It worsened, as 56 investors sold KEY shares while 237 reduced holdings. 72 funds opened positions while 164 raised stakes. 795.23 million shares or 0.32% more from 792.69 million shares in 2018Q3 were reported. 2.79 million were accumulated by Tiaa Cref Investment Mgmt Limited Liability. Kbc Gru Nv invested 0.02% of its portfolio in KeyCorp (NYSE:KEY). Tocqueville Asset Lp has 87,369 shares. Lourd Capital Ltd Liability holds 0.03% or 22,999 shares in its portfolio. Trillium Asset Limited Liability Com reported 924,074 shares. First Hawaiian Bank & Trust owns 0.03% invested in KeyCorp (NYSE:KEY) for 33,085 shares. Cramer Rosenthal Mcglynn Limited Liability Corporation stated it has 3.75 million shares. M&R Capital holds 0.02% of its portfolio in KeyCorp (NYSE:KEY) for 4,622 shares. Da Davidson & stated it has 200,867 shares or 0.06% of all its holdings. Arrow Financial Corp reported 812 shares. Alliancebernstein LP stated it has 0.02% in KeyCorp (NYSE:KEY). Great West Life Assurance Can reported 0.03% in KeyCorp (NYSE:KEY). 682,732 are owned by Tower Bridge Advisors. Atwood Palmer holds 0% in KeyCorp (NYSE:KEY) or 300 shares. Bp Public Limited Company holds 0.07% or 122,000 shares.

More notable recent KeyCorp (NYSE:KEY) news were published by: Seekingalpha.com which released: “Union Pacific: Why Q1 Earnings Are Key – Seeking Alpha” on March 18, 2019, also 247Wallst.com with their article: “Jefferies Franchise Picks Still Crushing S&P 500: 5 to Buy Now – 24/7 Wall St.” published on April 05, 2019, Globenewswire.com published: “New Research: Key Drivers of Growth for FedEx, Clearside Biomedical, Aaron’s, Lumber Liquidators, Timken, and Novanta — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” on April 15, 2019. More interesting news about KeyCorp (NYSE:KEY) were released by: Seekingalpha.com and their article: “BlackBerry: Key Earnings Report – Seeking Alpha” published on March 26, 2019 as well as 247Wallst.com‘s news article titled: “Big Banks in the Spotlight as Earnings Season Rolls Out – 24/7 Wall St.” with publication date: April 14, 2019.

Analysts await KeyCorp (NYSE:KEY) to report earnings on April, 18 before the open. They expect $0.42 earnings per share, up 10.53% or $0.04 from last year’s $0.38 per share. KEY’s profit will be $420.76 million for 9.92 P/E if the $0.42 EPS becomes a reality. After $0.48 actual earnings per share reported by KeyCorp for the previous quarter, Wall Street now forecasts -12.50% negative EPS growth.

Mariner Wealth Advisors Llc, which manages about $2.11B and $5.62B US Long portfolio, upped its stake in Southern Co (NYSE:SO) by 16,628 shares to 42,495 shares, valued at $1.87M in 2018Q4, according to the filing. It also increased its holding in Simon Ppty Group Inc New (NYSE:SPG) by 2,298 shares in the quarter, for a total of 5,294 shares, and has risen its stake in Invesco Qqq Tr.

Since November 1, 2018, it had 2 insider buys, and 1 sale for $147,440 activity. $92,750 worth of stock was bought by KIMBLE DONALD R on Friday, November 2. Another trade for 10,000 shares valued at $182,600 was bought by MOONEY BETH E.

KeyCorp (NYSE:KEY) Institutional Positions Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *